Samsung Epis Launches First China Biopharma R&D Center in Zhongguancun Life Science Park; Local Firms Surge Ahead in Financing, Clinical Advances, and Tech Breakthroughs

Jul 01, 2026 17:30 CST Updated 17:30

InnoCare

Innovative Drug Developer

MoleculeMind

AI Protein Design Platform Developer

SHUKUN

Provider of Intelligent Products and Innovative Solutions

Unicet Biotech

Developer of γδ T Cell Therapeutics

Insight into Global Trends, Understanding Frontier Dynamics

Into the Zhongguancun Life Science Park Monthly

Let’s Take a Look at the Latest News This Month

Recently,Samsung Epice Holdings Co., Ltd.—an investment holding company under the Samsung Group dedicated to advancing biopharmaceuticals and biotechnology innovation(Samsung Epis Holdings Co., Ltd.) (hereinafter referred to as "Samsung Epis"),Construction of the Biopharmaceutical R&D Center Officially Launched at the Synthetic Biology Manufacturing Translation Acceleration Center in Life ParkZhongguancun Life Science Park Development Co., Ltd. and Hong Kong-Shenzhen Innovation and Technology Park Company officially signed the “Memorandum of Cooperation” at Beijing Zhongguancun Life Science Park.

In addition, the 2026 Beijing·Changping Life Science Forum and the 43rd National Conference on Pharmaceutical Industry Information will be held at the Petroleum Science and Technology Exchange Center in Changping District, Beijing, from July 11 to 12!

Park Headlines | Beijing· The Changping Life Science Forum and the National Pharmaceutical Industry Information Annual Conference Join Forces Again!

Park Headlines | Zhongguancun Life Science Park and Hong Kong-Shenzhen Innovation and Technology Park Sign Strategic Cooperation Memorandum of Understanding——Deepening Cross-Regional Sci-Tech Collaboration to Jointly Build an Innovation Ecosystem for Life and Health

In June, the park’s enterprises received a steady stream of good news.

In terms of award recognition,CapitalBio Corp.The world’s first full-process technical specification for “discovering natural medicinal biological resources based on high-throughput transcriptome sequencing,” co-developed by the company, has been officially released. Yongxin Medical was awarded the Innovative Medical Device Award.

In terms of product R&D,"Beijing Brain No. 1"Nationwide pilot promotion will be launched next year.Qingyuan KaiwuThe Fully Automated Library Preparation Workstation Has Received Medical Device Registration Approval.SINEUGENEJointly established with Peking University Third Hospital, the Beijing Key Laboratory has been approved and recognized.InnoCareOver 40 studies on the independently developed novel BTK inhibitor orelabrutinib were presented at the 31st European Hematology Association (EHA) Annual Congress, marking the first demonstration of the efficacy and safety of orelabrutinib in treating previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in European and American populations; Phase III studies of tislelizumab-based combination therapy for previously untreated DLBCL showed a significant prolongation of progression-free survival.MoleculeMindMMDesign Released, Target Hit Rate Soars to 90%.SHUKUNApproved to lead the establishment of the “Beijing Key Laboratory of Digital-Intelligent Family Doctor Multi-Agent Systems for Chronic Disease Prevention, Control, and Health Management.”

In terms of the capital market,Unicet BiotechAnnounces Completion of Nearly RMB 200 Million in Series A Equity Financing. Investors in this round include Longpan Investment, Zhongguancun Capital, Beijing Pharmaceutical and Health Industry Investment Fund, Feitu Hongyuan, and Shenzhen Capital Group. The funds raised will be primarily used for clinical studies of core products, proof-of-concept for early-stage innovative pipelines, and the continuous iterative upgrade of the company’s proprietary γδ T cell technology platform.

In addition,Professor Wei Wensheng's Team at Changping LaboratoryThe RNA editing technology LEAPER, developed through R&D, has achieved internationally leading results in the treatment of Duchenne Muscular Dystrophy (DMD), a severe genetic rare disease. This marks the first time that China’s original RNA editing technology has entered clinical trials, as well as the first application of RNA editing for DMD treatment worldwide.Researcher Su Jun, Beijing Institute of Biological ProductsPublished a research paper in the internationally renowned journal Cell, in which the study achieved, for the first time, “high-definition” imaging of the entire five-day pre-implantation development of human embryos using internationally leading live-cell fluorescence microscopy techniques.

Capital Markets | From Ophthalmic Neuromodulation to Visual Brain-Computer Interfaces: i-Mu Technology’s i-NYS Goes Public and Completes Series D Financing

Xinhua News Agency Focus: Changping Laboratory’s Proprietary RNA Editing Technology Applied to Rare Disease Treatment for the First Time Worldwide

Cell! Su Jun’s Laboratory Reveals High-Definition Dynamics of the First 120 Hours of Human Life, Elucidates the Cell Biological Mechanisms Underlying Pre-implantation Embryonic Arrest, and Proposes Prevention and Treatment Strategies

Biotalks | Zhongfa Lingchuang: Empowering Hard-Tech Innovation and Industrial Upgrading with the “Industry + Capital + Service” Model

Corporate News | World’s First Full-Process Technical Specification for “Discovery of Natural Medicinal Biological Resources Based on High-Throughput Transcriptome Sequencing,” Co-Developed by CapitalBio, Officially Released

Corporate News | Surpassing Top International Models! MoleculeMind Unveils MMDesign, Target Hit Rate Soars to 90%

Corporate News | Over 40 Studies on Orelabrutinib Presented, Featuring the First Clinical Data of Orelabrutinib in Treatment-Naïve CLL/SLL Patients in Europe and the US

Corporate News | Phase III Study of Taletrectinib Combination Therapy in Previously Untreated DLBCL Shows Significant Prolongation of Progression-Free Survival

Corporate News | Yongxin Medical Wins Innovative Medical Device Award! Hard Power in Nuclear Medicine Technology Recognized Again

In June, Zhongguancun Life Science Park launched a series of industry activities, including "Zhi Hu Hang: Practical Guide to Criminal Compliance and Marketing System Restructuring for Biopharmaceutical Enterprises," the 2026 Zhongguancun Overseas Returnees’ Enterprise Premium Project Promotion Conference, and the Cell Analysis Technology Application Exchange Seminar, comprehensively supporting the high-quality development of enterprises.

Furthermore, to enhance young talents’ sense of belonging and gain, and to promote the resonance between block ecology and youth life,The First Cultural and Sports Event of the Young Talent Innovation and Entrepreneurship Ecosystem Zone in the Life Science Park Has Kicked Off! This event runs from mid-June to mid-July,Three “Park World Cup Second Venue” Series Viewing Events, each session includes four key modules: “core viewing experience + peripheral interactive challenges + non-alcoholic refreshments + fun predictions,” allowing fans of different teams to participate at various times. Meanwhile, 2The 2026 Zhongguancun Life Science Park Football and Basketball Super League has also kicked off., employee representative teams from various enterprises stationed in the industrial park gathered together, officially kicking off a ball-game sports feast belonging to the park’s strivers!

The Green Field Reignites, Answer the Call to Battle Again | "Ignite the Block, It's Your Turn to Play" Second Event Scheduled for June 29! Top 16 Spectator Viewing Simultaneously Launches

Talent Recruitment | Latest Job Openings from Beijing Institute for Brain Disorders, Beijing Institute for Life Sciences, and Changping Laboratory

Note: The data are sourced from public information. Please excuse any omissions.